ImageneBio cut its quarterly loss and said $126.6 million in cash should fund operations into the first quarter of 2028. Its studies remain on schedule, though it still lost $15.6 million; the cash and study progress make the report favorable.
The smaller loss and cash expected to last into early 2028 give ImageneBio time to advance its studies. Both study plans are on schedule. The company still lost $15.6 million, and no patient results were reported, so the update does not prove its treatments work.
Follow ImageneBio (IMA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IMA